Resources
Whitepapers
Replacing clinical trials and registries
Data quality
Truveta Data comprises billions of EHR data points, representing more than 120 million patient journeys from more than 20,000 clinics and 900 hospitals, updated daily. Truveta Data adheres to the highest standards of quality and provenance, supported by stringent quality control processes detailed in this whitepaper.
Truveta Language Model
Advancements in AI have presented a unique opportunity to transform and clean massive streams of healthcare data to make it available for research, innovation, and patient care. This whitepaper explains the Truveta Language Model, a large-language model used to clean billions of EHR data points for health research.
Accelerating research
The pace of research-driven medical progress has been slowed by difficulties in obtaining, cleaning, and analyzing clinical data. This whitepaper explores how Truveta Studio accelerates every step of the research process – from hypothesis to publication or regulatory submission – by providing immediate access to clean, high-quality, linked EHR data, powerful analytics, and AI.
Data security
Truveta’s advanced security systems protect Truveta Data through every stage of the data handling process and have been validated to meet the most rigorous standards for privacy and security. This whitepaper outlines how we manage the complex flow of health data to maintain customer and member health system trust.
Patient privacy
Founded by health systems, Truveta has a deep commitment to patient privacy. This whitepaper outlines how data flows from our health system members from the Truveta platform and the advanced measures taken to ensure patient privacy and protect against potential reidentification.
Powering device research
Medical device companies are challenged by a significant lack of real-world data on device use in clinical practice. In this whitepaper, learn how Truveta provides critical device specific information linked to deep clinical data to accelerate device research for over 150,000 unique medical devices.
Advancing cardiovascular research
Cardiovascular disease is a leading cause of death in the US, but researchers face many challenges when seeking to study the safety and effectiveness of drugs and devices used to treat it. This whitepaper highlights historical limitations of RWD and explains how Truveta addresses them to accelerate research on outcomes and care.
Truveta Mapper: A zero-shot ontology alignment framework
We share the technical details behind Truveta Mapper the underlying AI technology in the Truveta Language Model. Truveta Mapper leverages a multi-task sequence-to-sequence transformer model to perform alignment across multiple ontologies in a zero-shot, unified, and end-to-end manner. This paper was originally published at arXiv.
Ethics policy
We believe it is a moral imperative to harness the power of data to improve healthcare. We know we’ve taken on an enormous responsibility, and we pursue our work with a commitment to patient privacy, broadly enabling research and transparency about our data, all in close coordination with our member health systems.
Briefings
Beyond trials: How real-world dta is transforming autoimmune research
How real-world data is unlocking health insights
Advancing cardiovascular device research with Truveta Data
Combating respiratory viruses with EHR data: Key use cases for life sciences and public health
EHR data is rapidly changing how life sciences, pharmaceutical, and public health organizations monitor and respond to respiratory viruses. With Truveta Data, researchers gain access to real-time insights into respiratory viruses like influenza, RSV, and COVID-19 through de-identified EHR data from over 120 million patients.
Clinical notes
Many research questions can’t be fully answered without the detailed insights hidden in clinical notes. Truveta unlocks data from over 5 billion notes and integrates these datapoints with semi-structured EHR data, enabling novel research on safety, effectiveness, and more.
How real-world data is transforming GLP-1 research for diabetes and obesity care
GLP-1 medications are revolutionizing the way we treat type 2 diabetes and obesity. With Truveta Data, researchers gain access to RWD that provides comprehensive insights, addressing critical questions about the real-world performance of GLP-1 therapies.
Case studies and industry reports
Anti-seizure medications
Making data regulatory grade
Adoption of real-world evidence for regulatory decisions remains slower than necessary to meet growing industry demands. Truveta and Citeline surveyed life sciences leaders to uncover key barriers and opportunities for using real-world data in FDA submissions. This report highlights five critical insights from the survey and how Truveta is advancing regulatory-grade RWD.
Heart failure innovation
The lack of treatment evolution for heart failure (HF) is partly due to the difficulty and cost of studying complex inpatient interventions. This case study highlights how Reprieve Cardiovascular, a clinical-stage startup focused on decongestion for HF, partnered with Truveta to understand the current standard of care for HF to de-risk their pivotal clinical study and optimize trial protocols.
Assessing device safety
Despite promising clinical data for novel pulmonary embolism therapies, there are no randomized prospective studies comparing them and guidelines have not been updated to reflect real-world safety data. This case study showcases findings from a peer-reviewed study using Truveta Data to compare the safety of devices from Boston Scientific and Inari Medical.
Webinars
Advancing pregnancy safety research
This on-demand webinar demonstrates how regulatory-grade EHR data from over 120 million patients, including clinical notes and images, can overcome challenges in studying underrepresented populations, like pregnant people.
EHR data to advance care
In this webinar replay, hear how Boston Scientific has leveraged Truveta Data to study device safety and utilization for peripheral artery disease and pulmonary embolism, and gain insight into how this type of information can be used to drive device innovation, advance health equity, and inform clinical guidelines.
Raising the bar on real-world data quality: ensuring regulatory-grade EHR data
Learn why researchers are betting on EHR data as the future of real-world evidence generation and what to look for when evaluating the quality of a real-world dataset.
Uncovering disparities in access to popular treatments: insights from linked EHR and SDOH data
Explore how linked EHR and SDOH data are accelerating the identification of health disparities for type 2 diabetes, Alzheimer’s disease, and heart disease treatments
Enabling timely comparative effectiveness research: head-to-head analysis of GLP-1s for weight loss
See the results of a real-world GLP-1 comparative effectiveness study and the impact of timely and representative RWD in assessing performance of new therapies.
Driving therapeutic innovation and de-risking clinical development: The power of RWD from EHRs
Speakers from Truveta, Reprieve Cardiovascular, The Permanente Medical Group, and Stanford Cardiovascular Medicine discuss how Truveta Data is being used to drive product innovation for acute heart failure.
Transforming clinical research: Scaling real-world data across diseases with expert-led AI
Hear from experts at UCB and Truveta as they demonstrate the power of Truveta’s AI-driven extraction of critical information from free text clinical notes to further research at UCB.
Advancing clinical research through unprecedented data and learning community for health
Partnering with Fierce Pharma, hear from an expert panel on the power of unprecedented data and what early patient insights have been unveiled.
Featured research
A time-series analysis of anxiety diagnoses and prescriptions from January 2018 to January 2023
medRxiv
https://doi.org/10.1101/2023.12.21.23300415
Time-series analysis of first-time pediatric speech delays from 2018 to 2022
JAMA Pediatrics
doi:10.1001/jamapediatrics.2023.5226
Comparative effectiveness of semaglutide and tirzepatide for weight loss in adults with overweight and obesity in the US: A real-world evidence study
medRxiv
doi: https://doi.org/10.1101/2023.05.18.23290122